Patient subgroup | First-line regimen | n | Overall survival | Progression-free survival | ||||
---|---|---|---|---|---|---|---|---|
Median survival (months) | 95% CI | p | Median survival (months) | 95% CI | p | |||
Stage I-III at diagnosis | FOLFOX | 399 | 31.3 | 26.8-39.8 | 0.845 | 12.6 | 11.1-14.1 | 0.810 |
XELOX | 365 | 33.2 | 28.7-41.9 | 12.1 | 11.1-13.7 | |||
Stage IV at diagnosis | FOLFOX | 819 | 25.3 | 22.7-29.5 | 0.311 | 11.1 | 10.5-12.1 | 0.370 |
XELOX | 608 | 28.5 | 25.1-32.9 | 11.2 | 10.1-12.2 | |||
Without adjuvant chemotherapy | FOLFOX | 927 | 25.2 | 22.5-28.8 | 0.212 | 11.1 | 10.5-11.9 | 0.414 |
XELOX | 704 | 28.7 | 25.5-31.8 | 11.2 | 10.5-12.1 | |||
With adjuvant chemotherapy | FOLFOX | 288 | 36.2 | 29.0-44.4 | 0.744 | 13.1 | 11.2-14.8 | 0.883 |
XELOX | 262 | 35.8 | 28.2-43.8 | 12.1 | 11.1-14.0 | |||
Wild type KRAS | FOLFOX | 368 | 31.3 | 27.5-37.8 | 0.092 | 11.1 | 10.1-12.5 | 0.592 |
XELOX | 199 | 38.8 | 34.2-45.8 | 10.8 | 9.8-12.4 | |||
Mutant KRAS | FOLFOX | 230 | 31.5 | 28.9-37.7 | 0.309 | 12.7 | 11.7-14.5 | 0.084 |
XELOX | 123 | 28.4 | 22.9-42.2 | 10.0 | 9.3-11.9 |